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ABSTRACT 
 
Claire Reisig Hall: Annotation of the Understudied Kinome and  
Preliminary Testing of Kinase Inhibitor Combinations  
(Under the direction of Shawn Gomez) 
 
 A technique utilizing multiplexed inhibitor beads and mass spectrometry (MIB/MS) 
detects functional protein kinases in breast cancer cell lines.  Data from this technique was used to shed 
light on the understudied kinome, a portion of which is captured by the MIB/MS method. Regression 
analysis was performed to find correlations in kinase activity.  The functional linkages were then used to 
annotate the understudied kinases.  Annotations revealed new possible functions and disease relations 
for many understudied kinases. 
 Kinase inhibitor combinations were suggested by principle components analysis (PCA) results 
performed on MIB/MS data from treated breast cancer cell lines.   The combinations were preliminarily 
tested for signs of effectiveness.  Dose curves and growth assays were performed to compare drug 
combinations in the SKBR3 cell line. The interpretation of in vitro experiment results was impeded 
because of poor accuracy and reproducibility. Possible designs for in vitro experiments producing 
interpretable results are presented.  
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INTRODUCTION 
Cancer and treatment 
Cancer, a widespread and destructive disease with over 100 different types, is the second 
highest cause of death in the United States [1].  Breast cancer is the most common type of cancer, and is 
predicted to occur in over 250,000 new cases throughout the year 2017 [1].  For women, breast cancer 
has the second highest death rate behind lung cancer, meriting further research for understanding and 
treating the disease [1].  Breast cancer is separated into subgroups, emphasizing the heterogeneity of 
this type of cancer.  Subsequently, treatment is also heterogeneous, depending on the subtype and 
progression of the disease. From a clinical standpoint the subtypes are divided into luminal (further 
subdivided into luminal A and luminal B), HER2-enriched, and triple-negative [2]. These three major 
subtypes are classified via the presence or absence of three receptors, estrogen (ER), progesterone (PR) 
and human epidermal growth factor receptor 2 (HER2) [2]. Localized treatments include surgery and 
radiation therapy.  Systemic treatments are composed of drugs which circulate throughout the body via 
the bloodstream.  These treatments include chemotherapy, hormone therapy, or targeted therapy, and 
are often dependent on subtype.  Commonly, a combination of localized treatments and systemic 
treatments is used for combating breast cancer.    
 Chemotherapy consists of drugs which cause apoptosis by damaging DNA or inhibiting cell 
division.  Chemotherapy drugs generally target quickly dividing cells, a characteristic of cancer cells, thus 
enhancing the effectiveness of these drugs against cancer.  However, as these drugs are not selective to 
only cancer cells, they also may target quickly dividing non-cancerous cells, causing degenerative and 
severe side effects associated with current cancer treatment.  Drugs that can be targeted specifically to 
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the cancer cells thus minimize the side effects, but the available targets are dependent on the presence 
of receptors, and consequently, the subtype of breast cancer.  The luminal subgroup of cancer has at 
least one of the ER or PR receptors present and therefore hormone therapy is an effective form of 
treatment.  Hormone therapy inhibits the production or reception of hormone molecules, resulting in 
signal cascades within the cell causing cell cycle arrest or apoptosis.  The luminal subtype has the most 
optimistic prognosis [2].  HER2-enriched subtypes are also able to be targeted.  Drugs that target the 
HER2-enriched subtype, in most cases, competitively inhibit the binding site or activation site on the 
HER2 receptor. [3].  This again causes signaling within the cell to halt cell growth and/or begin apoptosis.  
The HER2-enriched subtype has a somewhat poorer prognosis than the luminal subtype primarily due to 
higher rates of recurrence [2].  Triple-negative breast cancers do not express the ER, PR, or HER2 
receptors.  Due to the lack of these receptors, no targeted therapies are currently FDA approved for 
triple-negative types of breast cancer, contributing to the very poor prognosis for this subgroup [3,2].   
Protein kinases and inhibitors 
One approach to targeted therapy of HER2-enriched breast cancer is through the use of a HER2 
kinase inhibitor.  HER2, also known as ERBB2, is a receptor tyrosine kinase [3].  Kinases are proteins 
heavily involved in signal transduction by means of phosphorylating substrate proteins. By 
phosphorylation, protein kinases are involved in activating, deactivating, and directing other proteins, 
along with orchestrating more complex cellular activity [4].  HER2 is part of the kinome, which consists 
of over 500 protein kinases [4].  The kinome makes up a vast, complex, signaling network and is essential 
in regular function and disease states within the cell.  The kinome controls cellular functions such as 
growth, proliferation, motility, and gene transcription.  Many kinases are abnormally regulated in 
cancers and are integral to the success of the disease [4].  Consequently, they can also be an integral 
part of treatment and successful remission of cancers.  Kinases are highly druggable due to presence of 
activation and phosphorylation sites.  By using targeted therapies, kinases’ functions may be suppressed 
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by inhibition.  Kinase inhibitors can affect a large range of kinases, spanning from very selective, 
targeting only a select few kinases, to broadly inhibiting many kinases.   Those which hit broadly are 
known to be more toxic in clinical settings, while those having a limited set of targets are generally more 
tolerable.   Despite these treatment options, the cell can redirect signaling through the kinome to 
circumvent the effects of the drug, referred to as reprogramming, and can result in drug resistant 
cancers [5].  Resistance can occur through different mechanisms, those that involve the kinome are 
generally a signaling pathway being reactivated via bypassing, parallel signaling, feedback reactivation or 
loss of negative feedback [6].  Other forms of resistance stem from the heterogeneity of cancers, not all 
cells in a tumor express the same proteins or kinases making it more difficult to kill all cancer cells with 
only one type of drug.  Chemotherapies and targeted therapies that work initially may lose effectiveness 
due to heterogeneity or reprogramming of the kinome.  Drugs with multiple targets, or drugs used in 
unison to attack multiple targets, may also fail due to the kinome’s ability to reprogram.  
Understudied kinases 
Of over 500 known protein kinases, up to half could be considered understudied depending on 
the set of criteria used.  Multiple elements are used in defining a kinase as having an understudied, or 
untargeted, status.  A definition set by Dr. Gary Johnson and collaborators at UNC-Chapel Hill designates 
229 protein kinases as being understudied due to lack of confirmed function, lack of disease and 
pharmacology association, and absence of direct biological tools to explore the kinase’s function 
experimentally [7].  Figure 1 depicts an overlay of the understudied kinases on a phylogenetic tree of the 
kinome.  This gives a visualization of how the understudied kinases are spread throughout the kinome, 
spanning all different kinase families.  
The NIH Illuminating the Druggable Genome (IDG) program has created a specific classification 
system for druggable proteins in the GPCR, nuclear receptor, ion channel and kinase families.  The target 
developmental level by the IDG organizes protein kinases into Tclin, Tchem, Tbio, and Tdark, all having 
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different criteria, some of which correspond with understudied kinases.  IDG classifies 31 kinases as 
Tdark due to the limited information available about them, including lack of publication, small molecule 
inhibitors, and gene references to functionality [8].  The program labels 163 kinases as Tbio, which 
means these kinases have more known of their function or phenotype than Tdark proteins but still do 
not have small molecules or drugs that adequately target them [8].  Tclin is composed of kinases known 
to be involved in disease and that are targeted by at least one FDA approved drug.  Tchem kinases have 
small molecule inhibitors available which target them and have documented functional studies 
concerning involvement in diseases [8]. The Tdark and Tbio categories along with the 229 understudied 
kinases defined by the Johnson lab will be explored further in this study as more needs to be understood 
about their function in the kinome and in disease states.    
Multiplexed inhibitor beads/mass spectrometry 
Commonly, protein presence is determined from gene expression profiling. However, this 
method can be misleading in the context of functioning or activated proteins, as is the case for kinases 
[9]. In this case, characterization of the level and activation state of proteins in the cell through 
proteomic techniques may prove more informative than genomic approaches.  A gene’s level of 
expression can be measured by the amount of messenger RNA (mRNA) found corresponding to the 
gene, where mRNA is transcribed from genes and then translated into proteins.  Because mRNA is an 
intermediate step, it is a poor representation of functional protein levels as there are many post-
translational modifications made to proteins [9]. Similarly, a high level of mRNA for a specific gene does 
not ensure a corresponding high level of the protein [10].  When examining protein kinase’s function, it 
is desirable to have a way of measuring the active protein in the cell rather than mRNA.  A method of 
depicting the functional kinases in breast cancer was generated by Dr. Gary Johnson and Dr. Lee Graves 
[11].   Samples can be composed of cell lines or patient tumor samples.  These samples are run via 
gravity-flow affinity chromatography over Sepharose beads each covalently linked with one of six 
 5 
different kinase inhibitors.  The system, called multiplexed inhibitor beads (MIB), extract functional 
kinases by binding them to the specific inhibitors, which are then distinguished using mass spectrometry 
(MS) [11].  By utilizing a specific combination of kinase inhibitors, over 360 different kinases are 
captured by the beads.    
Goals  
The aim of this investigation was to uncover functional linkages and associated annotation 
between understudied kinases from data acquired though MIB/MS.  In this work, the MIB/MS method 
gives a picture of the functional kinases present in normally cultured breast cancer cells, unperturbed by 
drugs, with a portion being kinases whose roles in the kinome are not fully known.  To utilize this data and 
shed light on the understudied kinome, regression analysis was performed to find correlations in kinase 
activity. Regression correlations were used to provide annotations for understudied, Tdark, and Tbio 
kinases.  Annotations revealed new possible functions for many kinases and also matched previously 
known annotations for some kinases. 
Secondly, kinase inhibitor combinations suggested by principle components analysis (PCA) 
results performed on MIB/MS data from treated breast cancer cell lines were preliminarily tested for 
signs of effectiveness.  This would be an improvement on current methods of choosing kinase inhibitor 
combinations, which show promise for cancer treatment.  Dose curves and growth assays were 
performed to compare drug combinations in the SKBR3 cell line. The interpretation of in vitro 
experiment results was impeded because of poor accuracy and reproducibility. Possible designs for in 
vitro experiments producing more clear results will be presented.  
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CHAPTER 1: REGRESSION AND ANNOTATION 
Introduction 
To investigate the function and disease relation of understudied kinases, the MIB/MS method 
was used to collect functional kinase data from 15 different breast cancer cell lines, with 2 or 3 replicate 
samples of each.  These cell lines were untreated and covered the three subtypes of breast cancer, 
luminal, HER2-enriched, and triple-negative. Of the 360 kinases detected by MIB/MS, 254 passed 
filtering for adequate presence in samples.  This represents approximately 70% of the kinases expressed 
in breast cancer, with 89 of the captured kinases being understudied, Tbio, and/or Tdark [7].  A small 
portion of this raw data can be seen in Table 1, with each column being a specific cell line and the rows 
being the MIB/MS value for the corresponding kinase.  A full representation of this data is portrayed in 
Figure 2 as a heat map, showing the data after normalization.  Each column is an average of the 
replicates of the 15 different breast cancer cell lines.  Each row is one of the 254 kinases which passed 
filtering.  The color represents the relative MIB/MS value for each specific kinase in each cell line with 
blue being minimum values and red maximum values.   
A key part of understanding all kinases’ functions is to learn the interactions connecting them in 
the signaling network.  Although not all kinase interactions are known, those documented in online 
databases were collected [7].  Protein-protein interactions involving kinases were acquired from HIPPIE, 
I2D, PhosphoSitePlus, and Reactome.  From the compiled data, 53 of the understudied kinases have zero 
reported known interactions, and almost two-thirds have less than five known interactions.   
Regression was performed using the MIB/MS data to find functional correlations between 
kinases throughout the breast cancer cell line samples.  These correlations along with the known kinase 
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interactions were used to annotate the understudied kinases, uncovering possible functions and 
relations to disease.   
Regression 
Regression analysis is used to create a model which estimates relations between variables.  In 
this case, a single kinase’s MIB/MS data represents the dependent variable (response vector), while the 
remaining kinase data composes the independent variables (input matrix).  The goal of estimating the 
relationship between kinases is to find the kinases associated by similar functional presence as 
portrayed through the MIB/MS data.  With a large set of data more than one viable relationship 
between the variables may exist.  Therefore, regression models can lead to over or under-fitted 
equations that do not accurately portray associations between variables [12].  Another difficulty is the 
presence of multicollinearity, or a high correlation between a subset of independent variables [12].   
Regression models have been developed to address the problems of multicollinearity and over-
fitting by penalizing the coefficient sizes and regularization [12].  Common models include lasso, elastic 
net, and ridge regression.  Differences lie in the penalties used by each model.  Lasso (Least Absolute 
Shrinkage and Selection Operator) regression adds an L1 penalty, also referred to as L1 norm, which 
limits the coefficient sizes.  The L1 penalty reduces some coefficients to zero, eliminating variables [13].  
Ridge regression adds an L2 penalty reducing all coefficients by the same scale [13].  Elastic net 
regression uses a linear combination of the L1 and L2 penalties, reducing some coefficients to zero (and 
eliminating variables) [13].  Because lasso and elastic net models reduce the number of variables used in 
the regression relationship these can be used as feature selection tools. Feature selection tools are 
models used to define the relevant independent variables in relation to the dependent variable [14]. 
They are commonly applied to data with many features and comparatively few samples, as in the data 
used here.  The models for lasso and elastic net assume independent samples, as is true for the MIB/MS 
data.  Although the problems of multicollinearity and over-fitting are not completely eliminated, the 
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significance of those pose a greater issue when creating a regression model primarily for its predictive 
power.  In this case, the primary goal of the regression model is to apply feature selection.   
Using the glmnet package in R software, elastic net and lasso were tested on normalized 
MIBs/MS data.  For both cases, the following equation was solved: 
  𝑚𝑖𝑛𝛽0,𝛽  
1
𝑁
∑ 𝑙𝑁𝑖=1 𝑤𝑙(𝑦𝑖, 𝛽0 + 𝛽
𝑇𝑥𝑖) + 𝜆[
(1−𝛼)||𝛽||2
2
2
+ 𝛼||𝛽||1]   Equation 1. [13] 
Where 𝑦𝑖  represents the vector of dependent variable data.  Figure 3A contains an example array of 
MIB/MS data, with the response vector, or 𝑦𝑖   highlighted in red.  The matrix of independent variables 
data forms 𝑥𝑖 and is highlighted in green in Figure 3A. In equation 1, the variable β is the result matrix of 
coefficients, highlighted yellow in Figure 3B.  The equation is solved for a set of values for λ, the tuning 
parameter which controls the overall strength of the penalty [13].  The penalty appears in the brackets 
to the right of λ.  The variable α controls the penalty in that an α of 1 performs a lasso regression while 
an α of 0 performs a ridge regression [13].  An α of 1 imposes a penalty equal to the absolute value of 
the magnitude of the coefficients.  An α of 0 introduces a penalty equaling the square of the magnitude 
of the coefficients. All values of α between 0 and 1 create a combination of both penalties for elastic net 
regression.  𝑙(𝑦, 𝜂) is the log-likelihood function, Gaussian by default, 
1
2
(𝑦 − 𝜂)2 [13].   
For testing, an alpha of 0.5 was used for elastic net regression as it is suitable for grouping 
closely correlated features into or out of the regression results together [13].  In contrast, lasso tends to 
have one coefficient out of a group remain in the results while all others in the group are reduced to 
zero [14].  A value of λ corresponding to 50% of the null deviance being explained was chosen for each 
run of the glmnet package.  The package has an option to run the algorithm using cross-validation to 
specify an optimal value of lambda creating the best predictive model.  Instead, lambda was chosen by 
consistency in null deviance explained because predictive accuracy of the model was not needed.  After 
testing, the number of resulting features with nonzero coefficients for each kinase was on average 14 ±
11 and 3 ± 2 for elastic net and lasso methods respectively.  Complete overlap between lasso and 
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elastic net was observed as expected, meaning all features in the lasso regression results were included 
in the elastic net regression results for each kinase.  Because lasso regression produces the most concise 
number of features, it was executed on each of the 254 kinases in the dataset by iteration as depicted in 
Figure 3C.   
Annotation 
After finding the features for all kinases, annotation was desired for the understudied kinases as 
detailed previously. To evaluate functional enrichment of a specific kinase, a group around the kinase 
was created using the results of the regression correlations.  The group for an understudied kinase 
consists of two parts.  The first portion is the regression features of the focus kinase, an example can be 
seen in Figure 3D.  By unifying regression results, the kinases in which the focus kinase was found as a 
regression feature are also included, portrayed in Figure 3E.  These together are referred to as primary 
features.  The second portion is composed of the primary feature kinases’ respective regression 
features, referred to as secondary features, seen in Figure 3F.  The group, formed of both primary and 
secondary features, was then entered into g:Profiler, an online server designed for analyzing sets of 
genes and providing gene ontology and pathway analysis/enrichment [15].  From the g:Profiler server, 
g:GOSt was used for evaluating enrichment tests.  Databases used are GO, KEGG, Reactome, miRBase, 
TRANSFAC, CORUM, BioGRID, HPA, HPO, and OMIM [15].  Collectively, these resources represent 
molecular pathways, target sites of miRNAs, target sites of transcription factors, protein complexes, 
protein-protein interaction networks, protein expression data, and physiological and disease 
phenotypes [15].   Enrichments are determined by applying hypergeometric distribution to calculate 
significant p-values for the molecular and functional representations above [15]. To reduce false 
positives with large backgrounds such as the whole genome, the g:SCS (Set Counts and Sizes) multiple 
testing correction threshold is used [15].   The g:SCS imposes a stronger threshold on each individual 
significance test in order to keep the collective p-value equal to 0.05.  To reduce the immense 
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background g:GOSt allows for the user to enter a unique background list of genes.  This was tested by 
entering the full list of kinase protein genes. The relatively small groups being analyzed for each kinase 
against the full list of kinases resulted in very few significantly enriched functions.  Instead, the default 
list of all human genes was used.  This did produce redundant and non-specific enrichments pertaining 
to general kinase function, such as signal transduction.  To avoid the majority of these non-helpful 
enrichments, only those found in the KEGG and Reactome pathways were further examined.   
In a final step, protein-protein interactions were added to the primary features of the networks 
created for Tdark kinases, example in Figure 3G.  The primary and secondary features along with any 
additional kinases associated by protein-protein interactions were entered into Panther for annotation.  
A list of 570 human kinase genes was used as a background list compared to the subnetworks of the 
Tdark kinases to find statistically overrepresented GO biological processes via Panther.  Panther is based 
on a cumulation of phylogenetic trees which allows useful annotations to be made for inquiry genes 
based on functions of other associated genes [16].  The gene set overrepresentation tool utilizes these 
annotations made from phylogenetics along with functional annotations available from the Gene 
Ontology Consortium [17].  A binomial test is applied to determine statistical over or under 
representation.      
Results and discussion 
The results of each 254 kinase’s lasso regression can be found in the Supplemental Data File S5 
link in the online preprint from Collins, et al [7].   A link to the full annotation results for each of the 89 
understudied kinases can be found within the Supplemental Data File S5, along with the abbreviated list 
of enriched functional pathways from KEGG and Reactome.  Also in the Supplemental Data File S5 is the 
protein-protein interactions found to be associated with the Tdark kinase subnetworks and their 
Panther annotation.  By evaluating the comprehensive list of g:Profiler annotations made for all 89 
understudied kinases, overarching observations were analyzed.  There were 363 unique annotations 
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from KEGG and Reactome found in all of the results.  These varied in regards to specificity of molecular 
function, pathways, or broad associations with disease.  Six kinases had no statistically enriched pathway 
annotations, and 23 had five or fewer annotations.  Many of these kinases had groups of regression 
features saturated with other understudied kinases; therefore the g:Profiler annotation tool was unable 
to recognize enough kinases to achieve statistical significance in annotations.  The average number of 
annotations per kinase was 41.  The most number of annotations for any kinase was 193 for CDK14.   
Annotations occurring for more than 25 kinases are shown in Figure 4, for example the common MAPK 
signaling pathway was an annotation result in 43 of the 89 kinases.  A brief portrayal of the range of 
annotations associated with many of the kinases can be viewed in Figure 4.  Although it only represents 
10% of the 363 different annotations, the combined frequencies, or total occurrence explained in Figure 
4, cover almost 30% of the total annotations across all understudied kinases.   
Despite the addition of kinases associated by protein-protein interactions to the Tdark 
subnetworks, the Panther annotation resulted in fewer statistically overrepresented functions due to 
the use of a kinase specific background list.  There were 34 different annotations in the results for the 
four Tdark kinases.  With ADCK1 having no annotations and SG196 having 24.  To illustrate more in-
depth results, four kinases from the Tdark category, present in the MIB/MS data, will be explored here. 
ADCK1 
Aarf domain containing kinase 1, ADCK1, is an understudied and Tdark kinase. 
 Current Knowledge 
ADCK1 has no confirmed kinase connections from the compiled network of protein-protein 
interactions.  ADCK1 has previously been associated with protein serine/threonine kinase activity and 
transferring phosphorous-containing groups by annotation as described by genecards [18].  No other 
information regarding the protein is available on databases such as Entrez, Uniprot or Panther.   
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 Annotations via regression 
ADCK1 had four primary regression features, shown in Table 2, along with 16 second order 
regression correlations.  This list of kinases was submitted to g:Profiler to uncover possible functional 
enrichment as discussed previously in the section.  From GO’s biological process and molecular function 
sources both protein serine/threonine kinase activity and transferring phosphorous-containing groups 
were annotated matching those previously known from genecards.  A visual of the connections for 
ADCK1 can be seen in Figure 5.  This subnetwork includes the list of regression linkages for ADCK1 from 
Table 2 and the protein-protein interactions of ADCK1’s primary regression features.  Additional 
statistically enriched annotations were neurotrophin signaling, insulin signaling, ErbB signaling pathway, 
FCER1 signaling pathway, colorectal cancer, endometrial cancer, prostate cancer, and the M phase of 
the cell cycle.  Panther annotation was performed on the full subnetwork list compared against the 
background list of 570 human protein kinases.  No statistically enriched annotations were uncovered. 
ADCK1’s subnetwork illustrates the sparse knowledge of kinase interactions. Many of the regression 
correlations are with other understudied kinases.  This demonstrates the difficulty in annotating kinases 
when so little is known about them and the kinases they are linked to.   
SG196 
Another Tdark kinase also falling in the understudied category is SG196, Sugen kinase 196 or 
Protein O-mannose kinase.  
 Current Knowledge 
The functional relevance proposed for this gene involves an association with alpha-dystroglycan 
protein, which establishes connections between the extracellular matrix and the exoskeleton [18].   
Experiments concerning SG196 divulged that mice with SG196 gene deficiency developed misplaced 
neurons in the brain [18]. It has also been related to several muscle dystrophy diseases [18].  As is 
typical for kinases SG196 also has annotations for transferase activity.  The kinase has two known 
 13 
interactions with proteins TGFR1 and BMR1B.  
 Annotations via regression 
 This kinase had seven primary regression features and 30 second order correlations, listed in 
Table 2.  These linkages can be seen in Figure 6, along with known interactions of SG196 and its primary 
regression features.  Significantly enriched in the regression features g:Profiler annotation were 
different aspects of metabolism, and various signaling pathways, such as: toll-like receptor, insulin, 
AMPK, IGF1R,PKB-mediated, and PI3K-Akt.  In agreement, ERBB2, a SG196 regression feature, dimerizes 
with other ERBB kinase proteins to form receptors involved in the PI3K-Akt pathway.  SG196 has only 
two known interactions, which in turn have known interactions with ERBB2.  Overlap of a known 
protein-protein interaction and a regression linkage between the same kinases, such as between K6PP 
and K6PL, is seen in SG196’s subnetwork (Figure 6).  Both of these proteins are involved in glycolysis 
[18].  Entrez suggests K6PP has a role in cancer via metabolic reprogramming [18].  A specific g:Profiler 
annotation for SG196 is central carbon metabolism in cancer.   
Panther annotation was performed on the list of regression features and protein-protein 
interactions involved in SG196’s subnetwork.  The resulting statistically overrepresented biological 
processes include ERBB signaling, MAPK signaling, and cellular response to stimulus.  
CSK23 
Also seen in Table 2 is Tdark kinase CSK23, Casein kinase II subunit alpha 3.  
 Current Knowledge 
CSK23 is known to be a part of the catalyzing subunit in a serine and threonine protein kinase 
complex of the casein kinase, which phosphorylates multiple substrates and is involved in Wnt signaling 
and DNA repair/cell cycle [18].  CSK23 is suspected to be associated with influenza A and lung cancer, by 
down-regulating the expression of PML, a tumor suppressor protein [18].  It has no known protein 
interactions in the compiled data.  
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 Annotations via regression 
 The kinase’s four primary regression linkages and 22 secondary feature linkages are listed in 
Table 2.  Although CSK23 had no direct known interactions, an additional 80 proteins were added to its 
subnetwork seen in Figure 7 via protein interactions with primary regression features. Through 
regression features, Wnt signaling was statistically overrepresented for CSK23 as was mentioned in its 
current knowledge above.  Other annotations were toll-like receptor, Ras, PI3K-Akt, and TNF signaling 
pathways.  Genecards reports the paralog gene for CSK23 to be CSK21, which is also a primary 
regression feature.  Both g:Profiler and Panther annotations showed NF-kappa B signaling as 
overrepresented along with immune related functions.  Both methods also had statistical 
overrepresentation in regulation of gene expression and condensation of prometaphase chromosomes 
which correlate to casein kinase’s involvement with DNA repair and cell cycle.   
M3KL4 
M3KL4 is a Tdark kinase, also known as MLK4, MAP3K21, or Mitogen-activated protein kinase 
kinase kinase 21.   
 Current Knowledge 
M3KL4 has only one known protein interaction with M3K10 and is reported via Genecards to be 
a paralog of M3K9.  The only annotations associated with M3KL4 currently are negative regulation of 
TLR4 signaling and non-activation of Jnk1/MAPK8 pathway, p38/MAPK14, or ERK2/MAPK21 [18].   
 Annotations via regression 
The regression features include six primary, 18 secondary connections, and 25 protein-protein 
interactions.  The regression features of M3KL4 are seen in Table 2 and its subnetwork is shown in 
Figure 8.   Panther and g:Profiler annotations revealed connections with MAPK pathways and immune 
system functions.  Other regression feature annotations were insulin signaling and synthesis of 
phosphatidylinositol phosphates (PIPs).   M3K9 is a primary regression feature of M3KL4 through lasso 
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regression, relating to the paralog connection stated from Genecards.   
Conclusions 
The ability to effectively understand and then perturb the kinome via targeted therapies is a 
promising and favorable route for cancer treatment.  To do this, more information concerning 
understudied kinases and the intricate signaling pathways of the kinome is necessary. Functional 
presence of kinases involved in breast cancer was measured via MIB/MS methods for 32 samples of cell 
lines.  Lasso regression was performed on these data as a succinct feature selection tool to find 
functional linkages between kinases.  These linkages were then used in an online annotation tool, 
g:Profiler, to find statistically overrepresented functions, pathways, and involvement in disease for 
understudied kinases present in the data.  The annotations were compiled to give better understanding 
and access to the results.  Additionally, known protein-protein interactions were added to the functional 
networks of four Tdark kinases.  The list of kinases in the subnetworks was used for annotation in 
Panther, compared against a list of 570 human kinases, to uncover statistically overrepresented GO 
biological functions.  This method showed correlation with annotations made from g:Profiler and with 
the few previously reported functions and annotations for the Tdark kinases.   
Overall the associated gene ontology annotations previously known for understudied kinases, 
concerning serine, threonine, or tyrosine kinase activity and transferase activity were consistently 
matched by the annotations performed with regression features. After examining details of four Tdark 
kinases’ results and comparing known interactions, functions and previously made annotations, there 
are positive indications that the regression linkages and annotations are functionally relevant and can be 
valuable in further exploration.  Commonalities also existed when considering known protein 
interactions associated with the Tdark kinases’ regression features.  New statistically significant 
annotations were made for many kinases, suggesting novel relevant functions and areas of possible 
investigation. 
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CHAPTER 2: KINASE INHIBITOR COMBINATIONS 
 Introduction 
 Targeting cancers with drug combinations using kinase inhibitors is thought to increase efficacy 
of treatment and reduce likelihood of reprogramming of the kinome.  Current methods of choosing drug 
combinations select a second drug based in its ability to target the upregulated kinases after 
perturbation from an initial drug [19].  This trial and error method of choosing drug combinations is 
inefficient and can be improved upon by using a more direct approach along with proteomic data 
instead of genomic data.   
Preliminary data was collected from samples of a breast cancer cell line treated with different 
kinase inhibitors.  MIB/MS protocol was used to find the change in kinase presence after perturbation 
compared to untreated control samples.  PCA analysis of the MIB/MS data resulted in drug treatment 
samples showing a shift in different sets of kinases.  Figure 9 shows the PCA plot of all samples.  Each 
PCA axis represents a different combination of kinases, therefore certain inhibitors alter the functioning 
kinases in different ways.  The sample of 100 nM Lapatinib moves the kinome response farthest on the 
PC3 axis.  Lapatinib is generally a low toxicity drug targeted primarily to ErbB2 (HER2) and ErbB1 (EGFR).  
The drug also hits ERK1, ERK2, and AKT kinases [20].  Lapatinib is an approved treatment for breast 
cancer.  The sample of 30 nM Dasatinib also moves the kinome response along the PC3 axis but to a 
lesser degree than Lapatinib.  Dasatinib causes some toxicity and broadly hits targets in the SRC family 
protein tyrosine kinases with a goal of primarily targeting BCR-ABL kinase [20].  It is an approved 
treatment for certain leukemias.  On the PC1 axis, the 100nM sample of BEZ235 causes a large 
difference in kinase expression compared to control samples.  Other chemical names for BEZ235 are 
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NVP-BEZ235 and Dactolisib.  BEZ235 has been reported as a highly toxic and non-effective drug in renal 
cell carcinoma, but has been indicated by research as a possible combination treatment breast cancer 
[21, 22].  BEZ235 targets PI3K and mTOR kinases [20].  GSK1120212 (Trametinib) altered a similar set of 
kinases to BEZ235, albeit less strongly, on the PC1 axis.  Trametinib is a low toxicity drug, targeting MEK1 
(MAP2K1) and MEK2 (MAP2K2) [20].  It is an approved treatment for melanoma and non-small cell lung 
cancer.  These four drugs were focused on to provide a proof of concept experiment as they portrayed 
the clearest changes in kinome signatures compared to control samples.   
Using MIB/MS and then PCA on treated samples could reveal optimal drug combinations by 
highlighting which inhibitors change the functional kinome in the strongest and most dynamic way.  In 
this case Lapatinib and BEZ235 are thought to be an effective drug combination based on results in 
Figure 9.  Experiments were performed using the same breast cancer cell line, HER2-enriched SKBR3, 
and kinase inhibitors Lapatinib, Dasatinib, BEZ235, and Trametinib.  Dose curves and growth curves were 
performed to evaluate the possible combinations of these drugs on SKBR3 cells.   
Methods  
 Dose curves were completed to find the dose of each drug which caused 30% inhibition in 
growth of the cells compared to a control sample.  This dose is referred to as the IC30.  Dose curves 
were completed in 96 well plates, SKBR3 cells were plated at 2000 cells/well with biological replicates of 
six for each sample.  Doses ranged on a logarithmic scale from 10 uM down to 1 nM.  The control 
samples were treated with 1% dimethyl sulfoxide (DMSO).  The cells were treated on Day 0 and Day 2, 
then imaged and counted on Day 4.  Ideal drug response curves follow a sigmoidal shape with percent 
affected versus the dose of drug.  However, in this case most dose curves do not follow a perfect shape, 
a more realistic result is shown in Figure 10A formatted to convey the % growth versus drug dose used 
in these experiments.  The IC30 is then calculated from the curve by reverting to a linear logarithmic 
scale, finding the dose which causes 70% growth compared to the DMSO control.  The growth assay is 
 18 
performed after IC30’s for each drug has been found.   
 Growth assays were completed to compare the growth of cells after treatment with different 
drug combinations giving preliminary assessment as to whether the MIB/MS and PCA method will be an 
improvement in determining optimal drug combinations.  Growth curves were completed in 96 well 
plates, SKBR3 cells were plated at 1000 cells/well with biological replicates of three for each sample.  
Samples consisted of each drug by itself and pairings of Lapatinib with each of the three other drugs.  
The IC30 dose for each drug was used in an individual sample and added to the IC30 of another drug for 
all combination samples.  The cells were treated, imaged and counted on Days 0, 2, 4, and 6.  Then the 
cells were imaged and counted on the final day, Day 8.  The ideal result for a growth curve using the 
drugs previously mentioned, can be seen in Figure 10B.  Percent growth, calculated by the average 
number of cells for a sample divided by the average number of cells for that sample on Day 0, is tracked 
every two days.  The key components of this ideal graph are that the single drug samples all grow 
approximately at the same pace and are close to 30% less than the DMSO sample on Day 4, expected 
due to the IC30 at day 4 from dose curves.  Secondly, the goal of the growth assay is to observe 
noticeable differences in drug combination samples, so as to determine if any of the combinations are 
more efficient at inhibiting growth than others.  Based on the PCA results of kinome changes in SKBR3 
cells after treatment with the four drugs (Figure 9) the combination of Lapatinib and BEZ235 is expected 
to inhibit growth the most, specifically compared to Lapatinib and Dasatinib which had similar kinases 
upregulated to a different degree, in contrast to Lapatinib and BEZ235 which alter different kinases.  If 
the Lapatinib and BEZ235 combination causes more efficient inhibition and therefore less growth, the 
methodology of using MIB/MS and PCA for choosing drug combinations may be a promising 
improvement on current trial and error methods.   
Results and discussion 
The first dose curves with appropriate shapes and IC30 dose results can be seen in Figure 11A-D.  
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The IC30 doses are displayed in the titles for each graph and were used for the first growth curve.  The 
growth curves produced using these IC30 doses are shown in Figure 12.  Although the individual drug 
samples of Lapatinib, Trametinib and Dasatinib did not inhibit growth to 70% exactly on Day 4, the 
growth trends were similar and comparable.  The individual drug sample for BEZ235 caused significantly 
more inhibition in the growth of the cells, causing the comparisons of drug combinations to be 
inaccurate.  Although the Lapatinib and BEZ235 combination did inhibit growth more than the other 
combinations, this observance is non-conclusive as the dose for BEZ235 caused similar inhibition by 
itself.  Because the IC30’s acquired from the previous dose curves did not produce the expected growth 
inhibition in the growth assay, the dose curve experiments were repeated.   
The earlier dose curves along with repetitions performed after the first growth assay, revealed 
flaws in the consistency and reproducibility of this technique in finding an IC30.  The dose curve for 
Lapatinib was performed only once (Figure 11A), the same IC30 dose of 9 nM was used two times in 
different growth assays with growth percent corresponding to 82% (Figure 12) and 62% (Figure 14).  
Compilation graphs of the dose curves completed for BEZ235, Dasatinib and Trametinib can be seen in 
Figure 13A-C.  The dose curve for BEZ235 was performed four times, with resulting IC30 doses ranging 
from 17 nM to 9 uM.  Two general trends of curve can be seen in Figure 13A.  The first two dose curves 
completed showed only 5 to 10% inhibition until much higher doses, giving IC30 doses of 6.5 uM and 9 
uM.  Due to these odd results, a new aliquot of BEZ235 was ordered and used in subsequent dose curves 
and growth assays.  The remaining two dose curves showed a more realistic shape and produced IC30’s 
from 17 nM to 50 nM.  The IC30 dose of 50 nM was used in the first growth curve, causing too much 
inhibition, only 50% at Day 4 (Figure 10), preventing accurate comparisons of combinations.  In a second 
growth assay a lower IC30 dose of 17 nM was used, causing similar inhibition at 53% on Day 4 (Figure 
14), again preventing comparison of combinations.  This is a prime example of how the discrepancy of 
IC30 doses between the dose curve to growth assays disrupted the results of the latter experiments.  
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Figure 13B illustrates the six repetitions of the dose curve for Dasatinib.  The IC30 doses ranged from 
230 nM to 2 uM.  Contrary to the case of BEZ235’s dose curves, all of Dasatinib’s dose curves follow a 
similar shape.  An initial IC30 dose of 600 nM was used which caused an appropriate growth of 65% on 
Day 4 (Figure 12).  In a following growth assay the same dose was used again causing growth of 88% on 
Day 4 (Figure 14).  Two of the five dose curves performed for Trametinib did not cause enough inhibition 
at the highest dose to calculate an IC30, shown in Figure 13C.  The first growth assay used an IC30 of 30 
nM for Trametinib, causing 86% growth at Day 4 (Figure 12).  The second assay used 50 nM, causing 83% 
growth at Day 4 (Figure 14).  These doses are appropriate but are in stark contrast to results of 10 uM 
causing over 70% growth in previous dose curves.   
The second growth assay performed can be seen in Figure 14.  Again, the Lapatinib and BEZ235 
combination inhibited growth by the most percentage as is expected, but comparisons of the drug 
combinations are inexact due to low growth of BEZ235, and the high growth of Dasatinib and 
Trametinib.  The discrepancy between inhibition caused by IC30 doses in dose curves versus growth 
assays could stem from experimental errors in preparing drug solutions or the difference in plating 
concentration and length of the experiments.   
Conclusions 
The kinome is a complex network of signaling which is an integral part of all cell survival.  Kinase 
inhibitors cause disruption to the signaling but due to pathway redundancies the kinome can reprogram, 
allowing the cell to carry on normal function.  Therefore, kinase inhibitors alone are not effective long 
term in treating cancers.  Inhibitors are given in combination to combat reprogramming.  Current 
methods of choosing combinations consist of finding kinase genes which are upregulated after 
treatment with an initial kinase inhibitor.  The combination kinase inhibitor is then chosen based on 
ability to target the upregulated kinases.  This is commonly a trial and error procedure and an inefficient 
process.   A possible new method of choosing drug combinations was investigated by performing in vitro 
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experiments in order to compare the suggested combinations.   
PCA was performed on MIB/MS data consisting of SKBR3 cells treated with various kinase 
inhibitors.  The resulting changes in the functional kinome produced differences in the samples in PCA, 
showing that Lapatinib and BEZ235 had different sets of kinases upregulated.  This suggests that the 
combination of Lapatinib and BEZ235 would inhibit growth of SKBR3 cells more than other combinations 
such as Lapatinib and Dasatinib which, to varying degrees, had a similar set of kinases changed.  To 
explore these drug combinations, dose curves and growth assays were performed.  Dose curves were 
used to compare a range of doses to percent growth measured against a DMSO control sample.  From 
this curve, IC30, a dose inhibiting growth by 30%, was calculated.  The IC30 doses were then used for 
individual drug samples and in combination samples for growth assays.  With all individual drug samples 
causing similar inhibition of growth the drug combinations can be compared by growth percent.  
Because of inaccurate and inconsistent inhibition by IC30 doses, directly comparing the growth of drug 
combinations was not possible.   
Possible remedies to the difficulties previously faced in performing experiments suggesting 
whether or not the MIB/MS and PCA method of choosing drug combinations is valuable is to perform 
dose curves and growth assays in the same experiment.  This would consist of a matrix of doses for each 
drug, and a matrix of combinations of all doses.  An inhibition of similar percentage would be found in 
the single drug doses, then that designated combination would be chosen to compare to another set of 
drugs combination.  This new protocol would eliminate the discrepancy in IC30 doses causing different 
inhibition and allow the combinations to be directly compared.   
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Figure 1.   Overlay of understudied kinases, shown in red, on the phylogenetic kinome tree [23].  This 
depicts the span of understudied kinases across all kinase families and reiterates the importance of 
understanding their function in order to understand the kinome network as a whole.   
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Figure 2.  Heat map of the normalized MIB/MS data used for regression.  Columns are an average of 2 or 
3 samples of each different breast cancer cell line.  Rows represent each of the 254 kinases which 
passed filtering.  The colors represent the specific MIB/MS value for the corresponding kinase in the 
corresponding cell sample, with red as a maximum and blue as a minimum.   
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Figure 3 (A-C).  Flowchart of methods for lasso regression and annotations.  (A) Example of normalized 
MIB/MS data for five kinase readings from five cell line samples.  The first iteration of lasso regression is 
performed with Kinase 1 (highlighted red) as the response vector and all other data as the input matrix 
(highlighted green).  (B) Example of resulting coefficient matrix after performing lasso, Kinase 1 is a 
function of regression features Kinase 3 and Kinase 4 with coefficients corresponding to the non-zero 
numbers in the area highlighted yellow.  (C)  The second iteration of lasso regression is performed with 
Kinase 2 (highlighted red) as the response vector and all other data (highlighted green) as the input 
matrix.   
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Figure 3 (D-G).  Flowchart of methods for lasso regression and annotations.  (D) Matrix of direct 
regression results, list of kinases which had non-zero coefficients for each kinase’s regression results.  (E) 
Matrix of primary regression results, representing each regression result in both regression lists of the 
two kinases involved.  (F) Matrix of full regression results, primary plus secondary which are the 
primary’s own regression features. (G) Example of network with primary and secondary regression 
correlations along with known protein-protein interactions.   
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Figure 4.  List of annotations occurring most frequently in throughout annotations of all understudied 
kinases, includes those which occurred in over 25 kinase annotations.  After compiling all KEGG and 
Reactome annotations from g:Profiler for 89 understudied kinases, the MAPK and PI3K-Akt signaling 
pathways occurred most often, in 43 and 39 different kinase annotations respectively.   
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Figure 5.  Subnetwork of regression features and protein interactions for ADCK1.  Well-studied kinases, 
16, are shown in gray and understudied, 9 including ADCK1, in green.  Known interactions are portrayed 
via a gray connecting line and regression linkages with red lines.  ADCK1 has no confirmed protein-
protein interactions and little known concerning its molecular or biological function other than its 
classification as a kinase.  By utilizing the regression linkages, signaling such as insulin and ErbB were 
found to be statistically over represented in kegg pathways.  Involvement in colorectal, endometrial, 
prostate cancer and M phase of the cell cycle were also results of the annotations.    
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Figure 6.  Subnetwork of regression features and protein interactions for SG196.  SG196 has 37 
regression correlations, shown in red, and an additional 91 kinases in its subnetwork pictured above in 
grey, from known protein-protein interactions.  A linkage between the same kinases by regression and 
protein-protein interactions is shown in pink.  Previously documented annotations for SG196 show 
involvement with muscle dystrophy diseases, abnormal neuron generation, and a connective protein 
alpha-dystroglycan.   SG196’s annotations via regression linkages and protein interactions include ErbB2 
signaling, PI3K-Akt signaling, IGF1R signaling, and mechanisms in metabolism.   
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Figure 7. Subnetwork of regression features and protein interactions for CSK23.  CSK23’s subnetwork 
consists of 26 regression linkages and 80 known interactions.  Known functions of CSK23 relate the 
protein to Wnt signaling, DNA repair in the cell cycle, and development of influenza A and lung cancer.  
Annotations using the subnetwork shown above reveal statistically overrepresentations in Ras, PI3K-Akt 
signaling, gene expression and condensation of prometaphase chromosomes, relating to the previously 
mentioned involvement in cell cycle.   
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Figure 8.  Subnetwork of regression features and protein interactions for M3KL4.  This subnetwork is 
composed of 24 regression linkages and 25 additional known interactions.  M3KL4 has been shown to 
negatively regulate TLR4 signaling, and does not activate specific pathways within the MAPK system.  
Annotations statistically overrepresented for M3KL4 were function in immune system, insulin signaling, 
and synthesis of PIPs.   
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Figure 9.  PCA plot of functional kinome changes in MIB/MS data of breast cancer cell lines after 
treatment with kinase inhibitors (Figure produced by Dr. Shawn Gomez). The three axes represent 
different sets of functional kinases present after perturbation.  The sample of 100 nM Lapatinib is 
pushed farthest along the PC3 axis while the sample of 100 nM BEZ235 is pushed farthest along the PC1 
axis.  These two treated samples have different sets of kinases being expressed and to the furthest 
degree compared to control samples.  The sample of 30 nM Dasatinib has a similar change in the 
functional kinome after treatment as 100 nM Lapatinib, to a lesser degree.  Similarly, 100 nM 
GSK1120212 (Trametinib) has shifted on the PC1 axis to a lesser degree than 110 nM BEZ235.  A 
combination of Lapatinib and BEZ235 is thought to be more efficient than combinations between 
Lapatinib, Dasatinib and Trametinib. 
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Figure 10 (A-B).  (A) Ideal dose curve for a kinase inhibitor.  Average growth of samples treated with 
different doses on a log scale are compared against the growth of a DMSO control sample.  The log 
curve can then be reverted to a linear equation to predict a dose causing 30% inhibition (IC30) for use in 
growth assays.  (B) Ideal growth assay for combinations between Lapatinib, Dasatinib, Trametinib and 
BEZ235.  All single drug samples show similar percent growth.  Lapatinib and BEZ235 combination 
expected to cause most inhibition or least percentage growth compared to a DMSO control.   
0	
1	
2	
3	
4	
5	
6	
day	0	 day	2	 day	4	 day	6	 day	8	
%
	G
ro
w
th
		
DMSO	
Lapa nib	
Dasa nib	
Trame nib	
BEZ235		
Lapa nib	+	Dasa nib	
Lapa nib	+Trame nib	
Lapa nib	+	BEZ235	
0	
20	
40	
60	
80	
100	
120	
0	 1	 3	 10	 30	 100	 300	 1000	 3000	 10000	
%
	o
f	
D
M
SO
	C
o
n
tr
o
l	
Dose	(nM)	
Kinase	Inhibitor	A	
B	
 33 
 
Figure 11 (A-D).  Dose curves used for calculating IC30’s for each drug used in the first growth assay.  
Dose curve experiments were repeated until a reasonable shape and dose resulted.  (A) Lapatinib, IC30 
of 9 nM.  (B) BEZ235, IC30 of 50 nM.  (C) Trametinib, IC30 of 30 nM.  (D) Dasatinib, IC30 of 600 nM.   
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Figure 12.  First growth assay for Lapatinib, Dasatinib, Trametinib and BEZ235.  Because of the low 
growth of BEZ235 (starred), the drug combinations concerning Lapatinib and BEZ235 were unable to be 
directly compared.  Although the most inhibitive was the combination of Lapatinib and BEZ235 this 
result was inconclusive as not all single dose samples caused similar growth.   
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Figure 13 (A-B).  Compilation of dose curves which were repeated for each of the drugs.  Each dose 
curve is represented by a separate line/color, with the legend detailing the date the curve was 
performed and its resulting IC30 dose.  (A) Compilation of dose curves completed for BEZ235.  (B) 
Compilation of dose curves completed for Dasatinib.  
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Figure 13 (C).  Compilation of dose curves which were repeated for each of the drugs.  Each dose curve is 
represented by a separate line/color, with the legend detailing the date the curve was performed and its 
resulting IC30 dose.  (C) Compilation of dose curves for Trametinib.   
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Figure 14.  Second growth assay performed for Lapatinib, Trametinib, BEZ235 and Dasatinib after dose 
curves were repeated for more accurate IC30 doses.  Despite repetition of dose curves for improved 
IC30 dose, drug combinations remained incapable of comparison due low growth of BEZ235 and high 
growth of Trametinib and Dasatinib (starred). Again, the combination of Lapatinib and BEZ235 did 
produce the most growth inhibition but was not a significant result.   
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Table 1.  Example matrix of raw MIB/MS data from four cell lines and only 30 out of the 254 kinases.  
The uniprot name of each kinase is located in the left column with each other column being a different 
cell line sample.  Each subtype of cancer is represented here including triple-negative (tnbc), HER2-
enriched, and luminals.   
 
 
 
claudin basal her2 luminal
tnbc tnbc her2/luminal her2/luminal
Uniprot SUM159_1 HCC1806_1 SKBR3_1 MCF7_1
AAK1 4626000000 1217000000 2230000000 13230000000
AAPK1 3446000000 981500000 2708000000 23970000000
AAPK2 891300000 348800000 2262000000 8639000000
ABL1 421400000 55820000 176400000 2271000000
ABL2 452800000 72080000 173400000 1638000000
ACK1 307100000 50920000 156200000 753500000
ACV1B 78780000 34060000 733200000 727000000
ACVR1 1405000000 39050000 0 2002000000
ADCK1 0 0 28790000 252700000
ADCK4 0 0 0 0
ADCK5 0 0 0 0
ADK 1050000000 319400000 1891000000 4209000000
AGK 49460000 0 0 355000000
AKT1 224000000 70780000 95020000 1631000000
AKT2 172800000 18600000 0 1516000000
AKT3 0 21180000 0 0
ARAF 369600000 78680000 222700000 1051000000
ATM 25470000 0 16870000 0
ATR 17570000 0 0 0
AURKB 485700000 121600000 614900000 289600000
AVR2A 46520000 13690000 0 0
BCKD 295400000 88940000 0 0
BLK 0 0 0 0
BMP2K 2460000000 384900000 528100000 3530000000
BMPR2 80890000 60040000 56590000 497200000
BMR1A 453100000 54480000 47360000 0
BMR1B 115100000 0 0 0
BRAF 407600000 103100000 339900000 2643000000
BRD2 11450000 0 0 0
BRD3 21350000 0 0 0
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Table 2.  Gene name, classification, and regression features of four Tdark kinases: ADCK1, CSK23, 
M3KL4, and SG196.  Information for the kinases listed is located in the Supplemental Data File S5 from 
Collins, et al, columns C, T, AM, and BK respectively [7]. 
Name 
AarF domain 
containing kinase 1 
Casein kinase II 
subunit alpha 3 
Mitogen-activated 
protein kinase 
kinase kinase 
Protein O-mannose 
kinase 
Uniprot ID ADCK1 CSK23 M3KL4 SG196 
Gene Name ADCK1 CSNK2A3 MAP3K21 POMK 
Classification Tdark/Understudied Tdark Tdark Tdark/Understudied 
Primary MRCKG   CSK21   CLK4 SIK3 NEK1 ERBB2 
Regression DMPK   IKKA   E2AK1 TYK2 PI3R4 K6PP 
Features KITM   PAK4   M3K9   PKN3 TIF1B 
  STK16   CSK22   PK3C3   STRAA   
2nd Order BRAF TESK1 ACVR1 MK13 BRAF STK11 AKT1 NEK1 
Regression CDK1   CDK14 MLTK CDK1 TAOK3 AVR2A P4K2B 
Features CSK22   CDK3 MP2K4 CHK1 TESK1 BMPR2 PDXK 
  DMPK   EGFR MRCKB DYR1A   BUB1 PI3R4 
  EPHB2   EPHB2 ST38L DYR1B   CLK3 PI51C 
  GSK3B   FER STK16 HYKK   E2AK4 PK3C3 
  HYKK   FGFR4 STK24 JAK1   ERN1 PKN3 
  IPMK   INSR   M3K1   IRAK4 PLK4 
  KITM   JAK1   M3K11   K6PL ST17A 
  M3K1   KAPCA   MLTK   K6PP ST32C 
  MK08   KT3K   PI3R4   KKCC2 STK11 
  PDPK1   LYN   PKN2   KSYK TESK1 
  PI4KA   M3K11   PLK4   KT3K TIF1B 
  PI51C   MARK2   SIK1   M3K1 TNIK 
  STK16   MK11   SIK2   M3K4 VRK2 
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